4SC is a biopharmaceutical company that uses its cheminformatics-based technology platform for the discovery and development of innovative drug candidates for the treatment of patients suffering from diseases with high medical needs. The company's therapeutic focus centres on cancer and inflammatory diseases as well as virus infections. The first project on the treatment of rheumatoid arthritis has completed clinical phase IIa. Additional projects in earlier stages are progressing towards clinical development. 4SC aims to realise the commercial potential of these programmes through licensing arrangements with pharmaceutical partners.
4SC was founded in 1997 and is listed in the Prime Standard Segment of the Frankfurt Stock Exchange.

Speaker Profile

Dr. Ulrich Dauer, Chief Executive Officer

Dr Dauer is a founding member of 4SC and took over the role as CEO in 1999. Prior to this he held a manager position at Tripos, a leading provider of screening libraries, software and systems integration in the life sciences business. In this role, he was responsible for key accounts and the acquisition of new business in Central and Eastern Europe. Dr Dauer earned his Doctorate in chemistry at the Institute of Organic Chemistry, University of Würzburg, Germany.